Purple Biotech PPBT, a clinical-stage oncology company, reported positive final results from the mid-stage study of its lead ...

Bristol Myers Squibb (BMY) is one of the stocks most watched by Zacks.com visitors lately. So, it might be a good idea to review some of the factors that might affect the near-term performance of the ...

We recently published a list of 10 Stocks That Are Close To Becoming Dividend Aristocrats. In this article, we are going to ...

Income investors are drawn to Aristocrats because these stocks have consistently increased their dividends for decades.

Bristol-Myers Squibb (NYSE: BMY) is the kind of stock that potentially has a lot to offer to investors looking for ...

It’ll be a busy December for dividend growth investors, with 25 companies announcing their annual increases. Check out the ...

Bristol Myers Squibb sues HRSA, claiming its rejection of a rebate model for 340B pricing violates federal law. The lawsuit highlights concerns over program abuse and regulatory overreach.

The issuer is solely responsible for the content of this announcement.

Wolfe Research has recently initiated Bristol-Myers Squibb Co (BMY) stock to Peer Perform rating, as announced on November 15, 2024, according to Finviz. Earlier, on November 13, 2024, Daiwa ...

There is more to the comparison, and in the sections below, we discuss why we think BMY will outperform JNJ in the next three ...